BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...for new autism medications in rat and mouse models 2013 Targets and biomarkers for antiepileptogenesis (EPITARGET...
BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

...to get their R&D projects going ( see "Selected public-private partnerships for November 2013"). The EPITARGET...
...Lund University; University of Veterinary Medicine, Vienna; European Commission Neurology €11.9 million ($16.1 million) Five-year EPITARGET...
BioCentury | Nov 25, 2013
Company News

Bioviron, Life & Brain, Microvitae Technologies, to-BBB, Academisch Medisch Centrum, Aix Marseille Universite, Ben-Gurion University of the Negev, Imperial Coll

...to identify biomarkers of epileptogenesis and develop therapeutics to prevent progression to epilepsy. The five-year EPITARGET...
BioCentury | May 28, 2012
Company News

Epitarget deal

...short interfering RNA molecules for Epitarget to test on its ultrasound triggered siRNA delivery platform. Epitarget...
...Health and Medical Research (Inserm) are responsible for in vivo testing. Details were not disclosed. Epitarget's...
...nano-sized liposomes, which can be released in tumors by exposure to a targeted ultrasound field. Epitarget A/S...
BioCentury | May 12, 2011
Distillery Techniques

Technology: Drug delivery

...ultrasound had less tumor growth than controls given doxorubicin-loaded liposomes without ultrasound. Upcoming publications from Epitarget A/S...
...approved to treat multiple cancers. SciBX 4(19); doi:10.1038/scibx.2011.554 Published online May 12, 2011 Patented by Epitarget...
BioCentury | May 9, 2011
Clinical News

Epitarget preclinical data

...growth compared to liposomal doxorubicin alone (p<0.05). Data were published in Journal of Drug Targeting. Epitarget A/S...
BioCentury | Jan 10, 2011
Company News

Epitarget management update

Epitarget A/S , Oslo, Norway Business: Cancer Hired: Derek Tobin as chief technology officer, formerly senior scientist at DiaGenic ASA WIR Staff cancer...
BioCentury | Nov 15, 2010
Company News

EDAP TMS S.A., Epitarget, INSERM deal

...and are now planning to enter preclinical testing. The ultrasound activated liposome is provided by Epitarget...
...acoustic/ultrasound research and EDAP is developing the HIFU device. EDAP TMS S.A. (NASDAQ:EDAP), Vaulx-en-Velin, France Epitarget A/S...
BioCentury | Oct 26, 2009
Emerging Company Profile

Epitarget: Bombarding Tumors with Sound

...only a fraction of that payload inside the tumor, limiting the effectiveness of the therapy. Epitarget A/S...
...far better than Caelyx in retarding tumor growth in the presence of ultrasound," she said. Epitarget's...
...inducing an irreversible conformational change in the liposomes that causes them to release their payload. Epitarget's...
BioCentury | Oct 26, 2009
Emerging Company Profile

Bombarding Tumors with Sound: Sidebar: Corporate Profile

Epitarget A/S Oslo, Norway Technology: Ultrasound-activated liposomes to deliver chemotherapeutics Disease focus: Cancer Clinical status: Preclinical Founded: 2007 by Esben Nilssen and Sigrid Fossheim University collaborators: INSERM , University of Tromsø and Norwegian Radium Hospital Corporate...
Items per page:
1 - 10 of 10
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...for new autism medications in rat and mouse models 2013 Targets and biomarkers for antiepileptogenesis (EPITARGET...
BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

...to get their R&D projects going ( see "Selected public-private partnerships for November 2013"). The EPITARGET...
...Lund University; University of Veterinary Medicine, Vienna; European Commission Neurology €11.9 million ($16.1 million) Five-year EPITARGET...
BioCentury | Nov 25, 2013
Company News

Bioviron, Life & Brain, Microvitae Technologies, to-BBB, Academisch Medisch Centrum, Aix Marseille Universite, Ben-Gurion University of the Negev, Imperial Coll

...to identify biomarkers of epileptogenesis and develop therapeutics to prevent progression to epilepsy. The five-year EPITARGET...
BioCentury | May 28, 2012
Company News

Epitarget deal

...short interfering RNA molecules for Epitarget to test on its ultrasound triggered siRNA delivery platform. Epitarget...
...Health and Medical Research (Inserm) are responsible for in vivo testing. Details were not disclosed. Epitarget's...
...nano-sized liposomes, which can be released in tumors by exposure to a targeted ultrasound field. Epitarget A/S...
BioCentury | May 12, 2011
Distillery Techniques

Technology: Drug delivery

...ultrasound had less tumor growth than controls given doxorubicin-loaded liposomes without ultrasound. Upcoming publications from Epitarget A/S...
...approved to treat multiple cancers. SciBX 4(19); doi:10.1038/scibx.2011.554 Published online May 12, 2011 Patented by Epitarget...
BioCentury | May 9, 2011
Clinical News

Epitarget preclinical data

...growth compared to liposomal doxorubicin alone (p<0.05). Data were published in Journal of Drug Targeting. Epitarget A/S...
BioCentury | Jan 10, 2011
Company News

Epitarget management update

Epitarget A/S , Oslo, Norway Business: Cancer Hired: Derek Tobin as chief technology officer, formerly senior scientist at DiaGenic ASA WIR Staff cancer...
BioCentury | Nov 15, 2010
Company News

EDAP TMS S.A., Epitarget, INSERM deal

...and are now planning to enter preclinical testing. The ultrasound activated liposome is provided by Epitarget...
...acoustic/ultrasound research and EDAP is developing the HIFU device. EDAP TMS S.A. (NASDAQ:EDAP), Vaulx-en-Velin, France Epitarget A/S...
BioCentury | Oct 26, 2009
Emerging Company Profile

Epitarget: Bombarding Tumors with Sound

...only a fraction of that payload inside the tumor, limiting the effectiveness of the therapy. Epitarget A/S...
...far better than Caelyx in retarding tumor growth in the presence of ultrasound," she said. Epitarget's...
...inducing an irreversible conformational change in the liposomes that causes them to release their payload. Epitarget's...
BioCentury | Oct 26, 2009
Emerging Company Profile

Bombarding Tumors with Sound: Sidebar: Corporate Profile

Epitarget A/S Oslo, Norway Technology: Ultrasound-activated liposomes to deliver chemotherapeutics Disease focus: Cancer Clinical status: Preclinical Founded: 2007 by Esben Nilssen and Sigrid Fossheim University collaborators: INSERM , University of Tromsø and Norwegian Radium Hospital Corporate...
Items per page:
1 - 10 of 10